Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer

37Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

Abstract

Context: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. Objective: We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. Design and Setting: We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. Main Outcome Measures: The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. Results: A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ(crude overall incidence, 2.7%). The incidence ofMRONJwas significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; Χ2=16.2; P

Cite

CITATION STYLE

APA

Sim, I. W., Sanders, K. M., Borromeo, G. L., Seymour, J. F., & Ebeling, P. R. (2015). Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. Journal of Clinical Endocrinology and Metabolism, 100(10), 3887–3893. https://doi.org/10.1210/jc.2015-1794

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free